4-iodobenzo[b]thiophene-2-carboxamidine hydrochloride | 149732-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 4-iodobenzo[b]thiophene-2-carboxamidine hydrochloride
• 英文别名: 4-iodo-1-benzothiophene-2-carboxiMidaMide hydrochloride；4-iodo-1-benzothiophene-2-carboximidamide;hydrochloride
• CAS: 149732-36-5
• 化学式: C₉H₇IN₂S*ClH
• 分子量: 338.599
• InChiKey: LSGFKADNXDPWBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-iodobenzo[b]thiophene-2-carboxamidine hydrochloride 、 4-碘苯并[b]噻吩-2-羧酸甲酯 在 bis(triphenylphosphine)palladium(II)-chloride CuI 作用下， 以 三乙胺 为溶剂， 以65%的产率得到methyl 4-[(benzo-1,3-dioxolan-5-yl)ethynyl]benzo[b]thiophene-2-carboxylate
  参考文献：
  名称：

  Urokinase inhibitors

  摘要：

  揭示了对抑制尿激酶活性有用的苯并噻吩和噻吩噻吩衍生物。

  公开号：

  US05340833A1
• 作为产物：
  描述：

  三甲基铝 、 甲烷 、 4-碘苯并[b]噻吩-2-羧酸甲酯 在 ammonium chloride 作用下， 以 甲醇 、 氯仿 、 甲苯 为溶剂， 生成 4-iodobenzo[b]thiophene-2-carboxamidine hydrochloride
  参考文献：
  名称：

  Urokinase inhibitors

  摘要：

  揭示了对抑制尿激酶活性有用的苯并噻吩和噻吩噻吩衍生物。

  公开号：

  US05340833A1

文献信息

• Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors
  申请人：Eisai Co., Ltd.

  公开号：EP0568289A2

  公开（公告）日：1993-11-03

  Disclosed are benzothiophene and thienothiophene derivatives useful for inhibiting urokinase activiy. Novel components of the formula : wherein R1 is H, NH2, or a halogen ; each R2-R5, independently, is a H, halogen, hydroxy, amino, nitro or organic group, provided that at least one R2-R5 is an organic group which includes 5 carbons or greater, an organic group which contains a sulfur atom or hydroxy, an unsaturated organic group, or a cyclic organic group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons of the formula : wherein R1 is H, NH2, or a halogen ; each R2-R5, independently, is a H, halogen, hydroxy, amino, nitro, or organic group, provided that at least one of R2-R5 is a group other than H, OH, NO2, CN, a halogen, an alkyl group of between 1 and 4 carbons, an alkoxy group of between 1 and 4 carbons, a haloalkyl group of between 1 and 4 carbons, a haloalkoxy group of between 1 and 4 carbons, an amino group, an amino group substituted with an alkyl group of between 1 and 4 carbons, a nitrile group, or a carboxamidine group, and further provided that no two adjacent R2-R5 groups together form a methylenedioxy group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons and of the formula : wherein at least one of X, Y, or Z must be C ; at least one of X, Y, or Z must be O, N, or S ; and, if more than one of X, Y, or Z is O, N, or S, then at least one of those groups is N ; R1 is H, NH2, or a halogen ; each R2, R3, or R5, independently, is a H, halogen, or organic group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons are described.

  公开了可用于抑制尿激酶活性的苯并噻吩和噻吩衍生物。式中的新成分......： 其中 R1 是 H、NH2 或卤素； 每个 R2-R5 分别是 H、卤素、羟基、氨基、硝基或有机基团、 但至少有一个 R2-R5 是包含 5 个碳原子或更多碳原子的有机基团、包含硫原子或羟基的有机基团、不饱和有机基团或环状有机基团；以及 每个 R6 和 R7 分别是 H 或式 1 至 6 碳原子的直链烷基： 其中 R1 是 H、NH2 或卤素； 每个 R2-R5 独立地为 H、卤素、羟基、氨基、硝基或有机基团、 条件是 R2-R5 中至少有一个是除 H、OH、NO2、CN、卤素、1-4 碳原子的烷基、1-4 碳原子的烷氧基、1-4 碳原子的卤代烷基、1-4 碳原子的卤代烷氧基以外的基团、氨基、被 1 至 4 个碳原子的烷基取代的氨基、腈基或羧酰胺基，且相邻两个 R2-R5 基团均不形成亚甲基二氧基......；且 每个 R6 和 R7 分别是 H 或 1 至 6 个碳原子的直链烷基，其式为......： 其中 X、Y 或 Z 中至少有一个必须是 C；X、Y 或 Z 中至少有一个必须是 O、N 或 S；如果 X、Y 或 Z 中不止一个是 O、N 或 S，则这些基团中至少有一个是 N； R1 是 H、NH2 或卤素； 每个 R2、R3 或 R5 分别是 H、卤素或有机基团；以及 每个 R6 和 R7 独立地为 H 或 1 至 6 个碳原子的直链烷基。
• USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES
  申请人：Menlo Therapeutics Inc.

  公开号：US20180235931A1

  公开（公告）日：2018-08-23

  The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, MK-0303 or MK-8478, in alleviating or suppressing cough (including acute, subacute and chronic cough) and urge to cough. The cough can have an unknown cause (idiopathic cough) or can be associated with any type of medical condition, such as a respiratory disorder. The NK-1 antagonist can be delivered by oral inhalation for more rapid peripheral and central antitussive action. Another antitussive agent in addition to the NK-1 antagonist can optionally be administered for the treatment of the cough or urge to cough, or the cough-associated medical condition.
• USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS
  申请人：MENLO THERAPEUTICS INC.

  公开号：US20190216779A1

  公开（公告）日：2019-07-18

  The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating acute or chronic pruritus associated with a variety of medical conditions, including dermatitis/eczema, psoriasis, prurigo, urticaria, cutaneous T-cell lymphoma, epidermolysis bullosa, bums and hepato-biliary diseases, or/and treating the medical conditions themselves. One or more additional antipruritic or therapeutic agents can optionally be used in combination with an NK-1 antagonist to treat acute or chronic pruritus associated with a medical condition or/and the medical condition itself.
• US5340833A
  申请人：——

  公开号：US5340833A

  公开（公告）日：1994-08-23
• Urokinase inhibitors
  申请人：Eisai Co., Ltd.

  公开号：US05340833A1

  公开（公告）日：1994-08-23

  Disclosed are benzothiophene and thienothiophene derivatives useful for inhibiting urokinase activity.

  揭示了对抑制尿激酶活性有用的苯并噻吩和噻吩噻吩衍生物。